Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model - Archive ouverte HAL Access content directly
Preprints, Working Papers, ... Year :

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

(1) , (2) , (2) , (2) , (1) , (1) , (1) , (2) , (2) , (1) , (1) , (3) , (1) , (4) , (2) , (1)
1
2
3
4

Abstract

Abstract Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatments are beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. One Sentence Summary The timing of type I interferon treatment is a critical determinant of its efficacy against SARS-CoV-2 infection.
Fichier principal
Vignette du fichier
2021.02.09.430458v1.full.pdf (3.38 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

anses-03387992 , version 1 (20-10-2021)

Identifiers

Cite

Pierre Bessière, Marine Wasniewski, Evelyne Picard-Meyer, Alexandre Servat, Thomas Figueroa, et al.. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. 2021. ⟨anses-03387992⟩
56 View
368 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More